Physician profile
Roy V Ditchey
NPI 1629044235
$836.67
in general payments reported to CMS, 2019-2025
18 companies · $114 in 2025
The $114 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $365 · 2020: $83.00 · 2022: $34.12 · 2023: $92.81 · 2024: $147 · 2025: $114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $354.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $354.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $129.79 | 2019 | |
| Amarin Pharma, INC. | $109.83 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $82.96 | 2019-2023 | Farxiga |
| Medtronic Vascular, INC. | $78.82 | 2019-2020 | |
| Medtronic, INC. | $69.83 | 2022-2025 | Mycarelink, Primo Mri Dr Surescan |
| Boston Scientific Corporation | $56.61 | 2023-2024 | Watchman Flx |
| Pfizer INC. | $48.04 | 2020-2025 | |
| Amgen INC. | $47.80 | 2019-2025 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $46.64 | 2019-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $23.43 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $21.81 | 2024 | Arcalyst |
| Alnylam Pharmaceuticals INC. | $20.55 | 2024 | Onpattro |
| United Therapeutics Corporation | $20.12 | 2024 | Orenitram |
| Cvrx, INC. | $17.52 | 2024 | Barostim Neo System |
| Esperion Therapeutics, INC. | $17.37 | 2025 | Nexletol |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $15.83 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Novo Nordisk INC | $15.25 | 2025 | Wegovy |
| Abbott Laboratories | $14.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roy Ditchey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.